DA
TEVA icon

DCF Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

DCF Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,500
Closed -$3.04M – 104
2025
Q4 		$3.04M Buy
+97,500
New +$2.4M 0.82% 32

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

DCF Advisers's TEVA Position: Q2 2026 in Review

DCF Advisers reduced its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, selling an estimated $1.52M and leaving 254,500 shares worth $8.62M. The position accounts for 1.52% of the portfolio, ranked #11.

DCF Advisers first reported a position in TEVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $12M in Q4 2025. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • DCF Advisers held 254,500 shares of Teva Pharmaceuticals worth $8.62M as of Q2 2026.
  • DCF Advisers sold 45,500 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.52M.
  • Teva Pharmaceuticals made up 1.52% of DCF Advisers's portfolio in Q2 2026, its #11 holding.
  • DCF Advisers first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • DCF Advisers's Teva Pharmaceuticals position peaked at $12M in Q4 2025.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.